Aptevo Therapeutics (APVO) – Analysts’ Weekly Ratings Updates

Aptevo Therapeutics (NASDAQ: APVO) recently received a number of ratings updates from brokerages and research firms: Aptevo Therapeutics Price Performance Shares of APVO stock opened at $0.18 on Tuesday. Aptevo Therapeutics Inc.

has a 12-month low of $0.14 and a 12-month high of $21.56.



The business has a 50-day moving average price of $0.35 and a two-hundred day moving average price of $1.06.

Aptevo Therapeutics ( NASDAQ:APVO – Get Free Report ) last released its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($1.67) EPS for the quarter, beating analysts’ consensus estimates of ($1.

93) by $0.26. On average, sell-side analysts forecast that Aptevo Therapeutics Inc.

will post -4.3 EPS for the current year. Institutional Trading of Aptevo Therapeutics Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States.

It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Recommended Stories Receive News & Ratings for Aptevo Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter .

.